Navigation Links
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Date:10/6/2008

dies that evaluated Durezol for the management of postoperative inflammation in which treatment was initiated one day prior to surgery. The multicenter, randomized, double-masked, placebo-controlled, parallel-group trials were conducted in 245 patients undergoing unilateral ocular surgery. In the first study of 124 patients, Durezol or placebo was dosed 4 times daily (QID), while in the second study, 121 patients received Durezol or placebo twice daily (BID).

"The Phase 3b studies represent an approach to therapy that is most similar to the current standard of care, meaning most physicians treat inflammation prophylactically rather than waiting for it to occur," explained Steven Silverstein, M.D. of Silverstein Eye Centers. Dr. Silverstein was a principal investigator in the QID study and also serves as a clinical assistant professor of ophthalmology at the University of Missouri-Kansas City School of Medicine and the University of Health Sciences. "Overall, the results from these studies show that by any definition utilized, Durezol administered both BID and QID was more effective than placebo in treating postoperative ocular inflammation and relieving ocular pain/discomfort as early as Day 3/4."

A significantly greater percentage of patients receiving Durezol QID or BID achieved a clinical response (defined as less than or equal to 5 anterior chamber cells and no flare) by Day 14: 81.3% of the Durezol treated patients in the QID group had a clinical response versus 25.0% of the placebo QID group (P < 0.0001); 74.7% of the Durezol BID patients had a clinical response versus 42.5% of patients in the placebo BID group (P < 0.001). Both Durezol groups maintained superiority over the placebo groups through Day 28, demonstrating that efficacy was definitive and did not decrease or reverse over time.

Ocular pain/discomfort was measured using the Visual Analogue Scale (VAS) score of 0-100 with 0 equal to no pain and 100 equal to maximal pain. The perc
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods ... increased 11% to $626 million. Q3 sales grew organically by ... organically by 4% and 2%, respectively.  Recently completed acquisitions contributed ... contributed an additional 5% to reported sales growth in Q3. ...
... Oct. 25, 2011 Abbott (NYSE: ABT ... – one undergraduate and one graduate – living with ... Undergraduate Student Scholarship, and Emily Kramer-Golinkoff, winner of the ... with CF who were eligible to receive the two ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 2Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 3
(Date:10/30/2014)... Lauderdale, FL (PRWEB) October 30, 2014 ... US Joint Commission Accredited teleradiology and specialty telemedicine ... that in addition to its existing teleradiology services ... multispecialty second opinion and expert telemedicine services, to ... Texas. , As a result of this innovative ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... When it comes to heart disease, a new study finds ... they have symptoms that spell trouble. "The main danger ... more severe or advanced stage of heart disease, there are ... Fulbright Scholar and research fellow at the Harvard School of ... and Stroke Foundation of Canada. In the study, researchers ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... your health, a new study reports. Previous research has ... and prevent osteoporosis. These benefits to bone health have led ... healthy diet. But this new study found that drinking ... from bone fractures, and was linked to an overall higher ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Americans, opinions about the ... a new study finds. Democratic voters are strongly ... to the researchers. Almost three-quarters of Democrats want the ... percent want Congress to implement the current law, while ... ACA. Among Independent voters, one-third want the law ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... Your Way, Contest and More than ... $10,000 in Cash and Prizes, HOFFMAN ESTATES, ... is the grand prize winner of the,annual "New Day Your Way" contest, ... and achieve their fitness goals,in 2008. During the 12-week contest, Kmart provided ...
... Researchers from the John Innes Centre and the University ... function of an enzyme which is involved in decorating ... variety of different carbohydrate molecules attached to them which ... the target organism or overcome resistance. By manipulating ...
... iron and offers a good set of proteins. This ... Eklund-Jonsson at the Department of Food Science, Chalmers University of ... a whole-grain product with high folate content. It is ... cardiovascular diseases, and it is also believed that it protects ...
... More Than $270 Million in Combined ... WALTHAM, Mass., May 28 Decision Resources, one ... pharmaceutical and,healthcare issues, forecasts that the Chinese type 2 ... to the new Emerging Markets report,entitled Type 2 Diabetes ...
... reach of drugs , , WEDNESDAY, May 28 (HealthDay News) ... provides a "hideout" for HIV during drug treatment and is ... cells (FDCs) are located throughout the body in specialized sites ... and Johns Hopkins School of Medicine. , FDCs act as ...
... of Recent Acquisitions; Continued Focus on ... Operational Efficiencies, SHENZHEN, ... NPD ) (,Nepstar, or ,the Company,), the,largest retail drugstore chain in ... March 31, 2008., Financial Highlights, For the first ...
Cached Medicine News:Health News:The Weight Is Over: Five Winners Lose 194 Pounds as Kmart Encourages 24,000 Americans to Achieve Healthier Lifestyle 2Health News:China's Type 2 Diabetes Drug Market Will More than Triple by 2012 2Health News:Scientists Break Into HIV 'Hideout' 2Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 2Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 3Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 4Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 5Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 6Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 7Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 8Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 9Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 10Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 11
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... lightweight brace is designed for the ... fractures. The anatomically correct design achieves ... for optimal control of ulnar segments. ... motion is permitted to prevent problems ...
Finger /Thumb Splint has a stay that may be shaped to hold finger or thumb in exact degree of flexion. It also has a contact closure....
... joint or DIP joint flexioncontractures of any degree. ... gel-lining cushions injured fingers so treatment to straighten ... more successful therapy results. Use during the day ... maintain gains in motion. Available in small, medium ...
Medicine Products: